The A-share innovative drug sector opened lower, with Harbin Sanlian Pharmaceutical and Harbin Pharmaceutical Group hitting the daily limit down, followed by Xin Ganjiang Pharmaceutical, Kangtai Biological Products, Haixin Pharmaceutical, CSPC Pharmaceutical Innovation, and Zhifei Biological Products.